II. Indications
III. Mechanism
- Interferes with Cytokine signalling on receptor binding
IV. Preparations
- Ruxolitinib or Jakafi (JAK1 and JAK2 Inhibitor)
- Indicated in Rheumatoid Arthritis and Myelofibrosis (including Polycythemia Vera)
-
Baricitinib or Olumiant (JAK1 and JAK2 inhibitor)
- Indicated in Rheumatoid Arthritis and Alopecia Areata
- Upadacitinib or Rinvoq (JAK1 inhibitor)
- Indicated in Rheumatoid Arthritis
- Tofacitinib or Xeljanz (JAK3 Inhibitor)
- Indicated in Rheumatoid Arthritis and Psoriasis
- Multiple black box warnings
- Serious infections
- Thrombosis (e.g. Venous Thromboembolism)
- Cardiovascular events (e.g. Myocardial Infarction)
- Lung Cancer
- Increased mortality
- References
- (2021) Presc Lett 28(4): 22
V. Adverse Effects
- Venous Thromboembolism
- Sudden cardiovascular death (associated with Tofacitinib)
-
Immunosuppression
- Tuberculosis reactivation risk (test for Latent Tb before starting)
- Increased risk of opportunistic infection (e.g. invasive fungal infections, Pneumonia, Shingles)
- Malignancy risk (e.g. Lymphoma)
VI. Precautions
- Avoid Live Vaccines
VII. References
- (2019) Presc Lett 26(10): 58
Images: Related links to external sites (from Bing)
Related Studies
| xeljanz (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| XELJANZ 5 MG TABLET | $89.28 each | |
| XELJANZ XR 11 MG TABLET | $178.55 each | |
| rinvoq (on 1/14/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| RINVOQ ER 15 MG TABLET | $183.59 each | |